At least 5 Danish based biotech companies could seek IPO in next 2 years  

2005.11.02
A new analysis by venture company Nordic Biotech shows that six Danish based biotech companies are expected to seek an IPO in the next 2 years

A new analysis by venture company Nordic Biotech shows that six Danish based biotech companies are expected to seek an IPO in the next 2 years, the majority of them on Copenhagen Stock Exchange. The companies, Life Cycle Pharma, Curalogic, Osteologix, Zealand Pharma, Gastrotech and 7TM Pharma have progressed their development of drugs further than expected.

Christian Motzfeldt, head of the Danish Fund for Industrial Growth, agrees in Nordic Biotech's conclusion and says: "I decline to disclose the names, but at least five companies will be stock exchange listed in the next 2 years. Five companies alone will have a total stock value of at least DKK 5 bn [USD 0.8 bn]".

Out of the six companies, Life Cycle Pharma is closest to bringing a drug to market. It plans to file for marketing approval of its cholesterol-lowering LCP-Feno compound in the US early in 2006. Curalogic plans to seek approval in 2007 in Germany for a capsule for allergy treatment with the aim of launching the drug on the European market in 2008. The news was reported by national daily newspaper Berlingske Tidende.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×